Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 9 clinical trials
SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

Study success is defined either on PFS or OS The primary objective is to determine whether SAR408701 improves the progression free survival (PFS) when compared to docetaxel in participants with metastatic non-squamous NSCLC expressing CEACAM5 2+ in intensity in at least 50% of the tumor cell population and previously treated …

non-small cell lung cancer
lung cancer
pulmonary metastasis
measurable disease
metastasis
  • 0 views
  • 04 Dec, 2020
  • 169 locations
SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients  

Study success is defined either on PFS or OS The primary objective is to determine whether SAR408701 improves the progression free survival (PFS) when compared to docetaxel in participants with metastatic non-squamous NSCLC expressing CEACAM5 2+ in intensity in at least 50% of the tumor cell population and previously treated …

non-small cell lung cancer
lung cancer
pulmonary metastasis
measurable disease
metastasis
  • 0 views
  • 21 Dec, 2020
  • 52 locations
Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

The participants will receive neoadjuvant PD-1 inhibitor (camrelizumab) combined with antiangiogenic drug (apatinib) or platinum-based chemotherapy.

blood transfusion
neutrophil count
pd-1 inhibitor
apatinib
cancer immunotherapy
  • 0 views
  • 16 Feb, 2024
  • 1 location
Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC neoSCORE

This is a Phase 2, prospective, randomized, open-Label, single-center international study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for resectable NSCLC. This trial will also explore the biomarkers of neoadjuvant immunochemotherapy.

neutrophil count
lung cancer
non-small cell lung cancer
paclitaxel
transient ischemic attack
  • 0 views
  • 05 Aug, 2020
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

adjuvant
immunomodulators
immunomodulator
sarcoma
endometrial carcinoma
  • 0 views
  • 16 Feb, 2024
  • 95 locations
Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer

This phase II trial studies how well platinum-based chemotherapy works when given together with durvalumab in treating patients with stage IIIB or stage IV non-small cell lung cancer.

stage iiib lung cancer ajcc v8
immunomodulators
uveitis
immunomodulator
metastasis
  • 0 views
  • 16 Feb, 2024
  • 2 locations
Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer

The addition of durvalumab to total neoadjuvant therapy (TNT) in locally advanced rectal cancer may improve the pathological complete response rate. The induction platinum-based chemotherapy may increase the neoantigen formation together with the chemoradiotherapy period. Starting durvalumab during the first chemotherapy session and continuing during the 6-week period of chemoradiotherapy …

vascular invasion
diverticulosis
diarrhea
adenocarcinoma of rectum
neutrophil count
  • 0 views
  • 16 Feb, 2024
  • 10 locations
Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)

Consequently, many of them are not able to withstand a platinum-based chemotherapy. The addition of taxanes to the armamentarium of drugs improve the outcome in this group of patients. An alternative and better tolerated regimen for these patients is paclitaxel in combination with cetuximab, included the in guidelines of the …

immunosuppressive agents
adjuvant
neutrophil count
major surgery
squamous cell carcinoma of unknown primary
  • 0 views
  • 16 Feb, 2024
  • 20 locations
Test Trial 002  

test comment here

  • 0 views
  • 05 Apr, 2023
  • 1 location